NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Vaccine Treatment of Kidney Cancer

Phase 2

Terminated

Conditions: Kidney Cancer

Interventions: Other: IL-2

First Posted Date: 2004-08-13

Last Posted Date: 2017-08-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT00089778

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: chemotherapy
Drug: oral sodium phenylbutyrate

First Posted Date: 2004-08-11

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00002909

Locations: 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States

Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: recombinant interferon alfa
Drug: omacetaxine mepesuccinate

First Posted Date: 2004-08-10

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 87

Registration Number: NCT00002574

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Docetaxel
Drug: Thalidomide
Drug: Prednisone
Biological: bevacizumab
Genetic: polymorphism analysis
Other: immunoenzyme technique
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2004-08-09

Last Posted Date: 2018-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 73

Registration Number: NCT00089609

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall

Phase 2

Terminated

Conditions: Recurrent Adult Soft Tissue Sarcoma
Stage I Adult Soft Tissue Sarcoma AJCC v7
Stage II Adult Soft Tissue Sarcoma AJCC v7
Stage III Adult Soft Tissue Sarcoma AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Dacarbazine
Radiation: Radiation Therapy
Drug: Doxorubicin Hydrochloride
Biological: Filgrastim
Drug: Ifosfamide
Drug: Thalidomide
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2004-08-09

Last Posted Date: 2018-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT00089544

Locations: 🇺🇸
Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States

17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas

Phase 1

Completed

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult T-cell Leukemia/Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Anaplastic Large Cell Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Grade 2 Follicular Lymphoma

Interventions: Drug: alvespimycin hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2004-08-05

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00089271

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer

Phase 3

Terminated

Conditions: Metastatic Head and Neck Cancer
Recurrent Head and Neck Cancer

Interventions: Drug: docetaxel
Other: placebo
Drug: gefitinib

First Posted Date: 2004-08-05

Last Posted Date: 2015-05-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 270

Registration Number: NCT00088907

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant

Phase 2

Completed

Conditions: Actinic Keratosis
Basal Cell Carcinoma of the Skin
Recurrent Skin Cancer
Squamous Cell Carcinoma of the Skin

Interventions: Drug: liposomal T4N5 lotion
Other: placebo
Other: laboratory biomarker analysis

First Posted Date: 2004-08-05

Last Posted Date: 2015-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT00089180

Locations: 🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

Phase 1

Terminated

Conditions: Extensive Stage Small Cell Lung Cancer
Recurrent Colon Cancer
Recurrent Non-small Cell Lung Cancer
Recurrent Rectal Cancer
Recurrent Small Cell Lung Cancer
Stage IV Colon Cancer
Stage IV Non-small Cell Lung Cancer
Stage IV Rectal Cancer

Interventions: Drug: recombinant fowlpox-CEA(6D)/TRICOM vaccine
Drug: recombinant vaccinia-CEA(6D)-TRICOM vaccine
Drug: sargramostim
Drug: docetaxel

First Posted Date: 2004-08-05

Last Posted Date: 2014-03-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00088933

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Phase 2

Completed

Conditions: Iris Melanoma
Stage IIC Melanoma
Stage IV Melanoma
Extraocular Extension Melanoma
Stage IIIC Melanoma
Ciliary Body and Choroid Melanoma, Medium/Large Size
Stage IIB Melanoma
Stage IIIA Melanoma
Stage IIIB Melanoma

Interventions: Biological: tyrosinase peptide
Biological: gp100 antigen
Biological: MART-1 antigen
Biological: incomplete Freund's adjuvant
Drug: Montanide ISA 51 VG
Biological: sargramostim
Other: laboratory biomarker analysis

First Posted Date: 2004-08-05

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00089063

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

AI-Powered Research

Premium Access

NATIONAL INSTITUTES OF HEALTH

Vaccine Treatment of Kidney Cancer

Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma

Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall

17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas

Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer

T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma